ABEONA THERAPEUTICS INC. Interest Expense
ABEONA THERAPEUTICS INC. (ABEO) reported Interest Expense of $696.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:InterestExpense · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. interest expense for the quarter ending 2026-06-30 was $696.00K, a 27.27% decline year-over-year.
- ABEONA THERAPEUTICS INC. interest expense for the quarter ending 2026-03-31 was $830.00K, a 16.83% decline year-over-year.
- ABEONA THERAPEUTICS INC. interest expense for the quarter ending 2025-12-31 was $884.00K, a 18.30% decline year-over-year.
- ABEONA THERAPEUTICS INC. interest expense for the quarter ending 2025-09-30 was $901.00K, a 18.24% decline year-over-year.
- ABEONA THERAPEUTICS INC. interest expense for fiscal 2025 was $3.74M, a 11.12% decline from fiscal 2024.
- ABEONA THERAPEUTICS INC. interest expense for fiscal 2024 was $4.21M, a 906.70% increase from fiscal 2023.
- ABEONA THERAPEUTICS INC. interest expense for fiscal 2023 was $418.00K, a 43.21% decline from fiscal 2022.
- ABEONA THERAPEUTICS INC. interest expense for fiscal 2022 was $736.00K, a 79.87% decline from fiscal 2021.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $696.00K 10-Q · filed 2026-08-13 | $1.53M 10-Q · filed 2026-08-13 | $2.41M derived: sum of 3 quarters · filed 2026-08-13 | $3.31M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $830.00K 10-Q · filed 2026-05-13 | $1.71M derived: sum of 2 quarters · filed 2026-05-13 | $2.62M derived: sum of 3 quarters · filed 2026-05-13 | $3.57M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $884.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.78M derived: sum of 2 quarters · filed 2026-03-17 | $2.74M derived: sum of 3 quarters · filed 2026-08-13 | $3.74M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $901.00K 10-Q · filed 2025-11-12 | $1.86M derived: sum of 2 quarters · filed 2026-08-13 | $2.86M 10-Q · filed 2025-11-12 | $3.94M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $957.00K 10-Q · filed 2026-08-13 | $1.96M 10-Q · filed 2026-08-13 | $3.04M derived: sum of 3 quarters · filed 2026-08-13 | $4.14M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $998.00K 10-Q · filed 2026-05-13 | $2.08M derived: sum of 2 quarters · filed 2026-05-13 | $3.18M derived: sum of 3 quarters · filed 2026-05-13 | $4.25M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.18M derived: sum of 2 quarters · filed 2026-03-17 | $3.26M derived: sum of 3 quarters · filed 2026-03-17 | $4.21M 10-K · filed 2026-03-17 | |||
| 2024-09-30 | $1.10M 10-Q · filed 2025-11-12 | $2.17M derived: sum of 2 quarters · filed 2025-11-12 | $3.13M 10-Q · filed 2025-11-12 | $3.23M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $1.07M 10-Q · filed 2025-08-14 | $2.02M 10-Q · filed 2025-08-14 | $2.13M derived: sum of 3 quarters · filed 2025-08-14 | $2.24M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $952.00K 10-Q · filed 2025-05-15 | $1.06M derived: sum of 2 quarters · filed 2025-05-15 | $1.17M derived: sum of 3 quarters · filed 2025-05-15 | $1.27M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $214.00K derived: sum of 2 quarters · filed 2025-03-20 | $317.00K derived: sum of 3 quarters · filed 2025-03-20 | $418.00K 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $105.00K 10-Q · filed 2024-11-14 | $208.00K derived: sum of 2 quarters · filed 2024-11-14 | $309.00K 10-Q · filed 2024-11-14 | $487.00K derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $103.00K 10-Q · filed 2024-08-12 | $204.00K 10-Q · filed 2024-08-12 | $382.00K derived: sum of 3 quarters · filed 2024-08-12 | $539.00K derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | $101.00K 10-Q · filed 2024-05-15 | $279.00K derived: sum of 2 quarters · filed 2024-05-15 | $436.00K derived: sum of 3 quarters · filed 2024-05-15 | $636.00K derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $335.00K derived: sum of 2 quarters · filed 2024-03-18 | $535.00K derived: sum of 3 quarters · filed 2024-03-18 | $736.00K 10-K · filed 2024-03-18 | |||
| 2022-09-30 | $157.00K 10-Q · filed 2023-11-13 | $357.00K derived: sum of 2 quarters · filed 2023-11-13 | $558.00K 10-Q · filed 2023-11-13 | $611.00K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $200.00K 10-Q · filed 2023-08-08 | $317.00K 10-Q · filed 2022-08-11 | $401.00K 10-Q · filed 2023-08-08 | $518.00K 10-Q · filed 2022-08-11 | $454.00K derived: sum of 3 quarters · filed 2023-08-08 | $1.14M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $201.00K 10-Q · filed 2023-05-11 | $254.00K derived: sum of 2 quarters · filed 2023-05-11 | $937.00K derived: sum of 3 quarters · filed 2023-05-11 | $2.44M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $736.00K derived: sum of 2 quarters · filed 2023-03-29 | $2.24M derived: sum of 3 quarters · filed 2023-03-29 | $3.66M 10-K · filed 2023-03-29 | $3.67M 10-K · filed 2022-03-31 | ||
| 2021-09-30 | $683.00K 10-Q · filed 2022-11-14 | $2.18M derived: sum of 2 quarters · filed 2022-11-14 | $3.60M 10-Q · filed 2022-11-14 | $4.99M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $1.50M 10-Q · filed 2022-08-11 | $2.92M 10-Q · filed 2022-08-11 | $4.31M derived: sum of 3 quarters · filed 2022-08-11 | $5.63M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $1.42M 10-Q · filed 2022-05-13 | $2.81M derived: sum of 2 quarters · filed 2022-05-13 | $4.13M derived: sum of 3 quarters · filed 2022-05-13 | $4.93M derived: sum of 4 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $2.71M derived: sum of 2 quarters · filed 2022-03-31 | $3.52M derived: sum of 3 quarters · filed 2022-03-31 | $4.12M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $1.33M 10-Q · filed 2021-11-15 | $2.13M derived: sum of 2 quarters · filed 2021-11-15 | $2.73M 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $800.00K 10-Q · filed 2021-07-28 | $1.40M 10-Q · filed 2021-07-28 | |||||
| 2020-03-31 | $600.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |